Scotiabank Initiates Coverage On Apellis Pharmaceuticals with Sector Perform Rating, Announces Price Target of $35

Benzinga · 10/16 14:46
Scotiabank analyst Greg Harrison initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform rating and announces Price Target of $35.